Market Tracker

12/09 5:16pm ET

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

42.25
Delayed Data
As of Dec 09
 +1.45 / +3.54%
Today’s Change
31.38
Today|||52-Week Range
101.81
-55.12%
Year-to-Date
2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November
Dec 07 / MotleyFool.com - Paid Partner Content
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Dec 04 / MotleyFool.com - Paid Partner Content
Alnylam Reports Positive Data on Fitusiran, Givosiran
Dec 05 / Zacks.com - Paid Partner Content
3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
Dec 01 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close40.81
Today’s open41.29
Day’s range41.11 - 43.58
Volume1,401,075
Average volume (3 months)1,350,106
Market cap$3.6B
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-39.99%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book2.84

Competitors

 Today’s
change
Today’s
% change
AGNPRAAllergan plc+13.10+1.87%
ENDPEndo International P...-0.01-0.06%
GRFSGrifols SA+0.10+0.68%
PTHNPatheon NV-0.02-0.07%
Data as of 4:03pm ET, 12/09/2016

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)-$1.32
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts